Steve Lawrence Meyers - 11 Jun 2025 Form 3 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Commercial Officer
Signature
/s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers
Issuer symbol
OCUL
Transactions as of
11 Jun 2025
Net transactions value
$0
Form type
3
Filing time
23 Jun 2025, 21:12:26 UTC
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meyers Steve Lawrence Chief Commercial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers 23 Jun 2025 0002073994

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUL Common Stock 152,728 11 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUL Stock Option (Right to Buy) 11 Jun 2025 Common Stock 45,000 $5.22 Direct F2
holding OCUL Stock Option (Right to Buy) 11 Jun 2025 Common Stock 100,000 $3.88 Direct F3
holding OCUL Stock Option (Right to Buy) 11 Jun 2025 Common Stock 145,000 $5.18 Direct F4
holding OCUL Stock Option (Right to Buy) 11 Jun 2025 Common Stock 222,000 $7.44 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 11,111 restricted stock units ("RSUs") remaining unvested pursuant to an award of 33,333 RSUs granted under the 2021 Stock Incentive Plan, as amended (the "Plan"), of Ocular Therapeutix, Inc. (the "Corporation") on January 30, 2023; 32,206 RSUs remaining unvested pursuant to an award of 48,309 RSUs granted under the Plan on February 3, 2024; and 74,000 RSUs remaining unvested pursuant to an award of 74,000 RSUs granted under the Plan on February 11, 2025. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 This option was granted on April 4, 2022 and vests over four years, with 1/4 of the shares underlying the option having vested on March 15, 2023 and 1/48 of the shares vesting monthly thereafter.
F3 This option was granted on January 30, 2023 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
F4 This option was granted on February 3, 2024 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
F5 This option was granted on February 11, 2025 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

Remarks:

Exhibit 24 - Power of Attorney